NCT00088101已完成1 期
Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 15
研究概览
简要总结
The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients 18 years or older with one of the following malignancies:
- •Histologically or cytologically confirmed hematological malignancy (other than Acute Myeloid Leukemia and Myelodysplastic Syndrome) and if treatment is medically indicated, or,
- •Histologically-confirmed non-hematological malignancy that is metastatic or unresectable and for which no standard therapy is available.
- •Patients with CLL, PLL, CML, CTCL, ATL, and Non-Hodgkin's Lymphoma may be entered if they are refractory to or have relapsed following conventional chemotherapy regimens such as alkylating agents (e.g. chlorambucil and cyclophosphamide), anthracycline combinations [e.g. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)], and/or purine analogues (e.g. fludarabine monophosphate and 2-CDA) and are not currently being considered for re-treatment with conventional regimens
- •Patients with CLL and other leukemic malignancies will be staged according to the modified Rai staging criteria [low-risk, intermediate-risk and high risk]. All patients in the high-risk group (Stage III and IV) are eligible. Intermediate risk patients (Stage I and II) with one or more criteria of active disease (such as progressive lymphocytosis, lymphadenopathy, and splenomegaly, weight loss > 10% within 6 months, extreme fatigue, fever and/or night sweats without evidence of infection, etc.) are also eligible
- •ECOG Performance Status of 0-2
- •Life expectancy of greater than 12 weeks.
- •Patients must have acceptable organ and marrow function at screening and pre-dose visits as defined below unless approved medically by the clinical investigator.
- •Absolute neutrophils count greater than 1,000 cells/ul for patients with hematologic malignancies and ≥1,500 cells/ul for patients with solid tumors
- •Platelets greater than 100,000/ul
- •Hgb greater than 8.5 g/dL
- •Total bilirubin must be <1.5 mg/dL or < 2X upper limit of normal
- •AST (SGOT) < 2.5 times the upper limit of normal
- •ALT (SGPT) < 2.5 times the upper limit of normal
- •Adequate renal function (serum creatinine < 2.0 mg/dL or a calculated creatinine clearance greater than 50 mL/min)
- •Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator.
- •NCI grade 0-1 left ventricular ejection fraction within 30 days of dosing.
- •The effects of STA-5312 on the developing human fetus are unknown. Therefore, women of childbearing potential (defined as women under 50 years of age or history of amenorrhea for < 12 months prior to study entry) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform the treating physician immediately.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Women who are pregnant or lactating.
- •Patients who have had chemotherapy, radiotherapy (except palliative radiation delivered to < 20% of bone marrow), immunotherapy, or corticosteroids ( > 10 mg/day of prednisone or equivalent) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •The use of nitrosoureas or mitomycin C within 6 weeks prior to study entry.
- •Patients with prior peripheral blood stem cell rescue or bone marrow transplantation.
- •History of primary brain tumors or active brain metastases. (Patients with previously treated brain metastases who are not receiving corticosteroids or anticonvulsants may be considered for enrollment)
- •History of stroke or other significant neurologic limitations within 6 months prior to study enrollment
- •Use of any investigational agents within 4 weeks of study enrollment.
- •History of severe allergic reactions to excipients (e.g. Tween 80) or had hypersensitivity reactions to other chemotherapeutic agents similar in structure to STA-
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
- •History of active CNS-lymphoma, AIDS-related lymphoma, or any uncontrolled severe medical illness or infection.
- •Grade 2 or higher sensory or motor neuropathy at screening.
- •Major surgery (excluding that for diagnosis) within 4 weeks of enrollment.
研究者
研究点 (15)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT00276913Synta Pharmaceuticals Corp.30
已完成
1 期
STA-4783 and Paclitaxel for Treatment of Solid TumorsNeoplasmsNCT00088114Synta Pharmaceuticals Corp.50
已完成
2 期
Safety and Efficacy of AST-120 in the Treatment of PouchitisPouchitisNCT00583076Ocera Therapeutics19
终止
2 期
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaMultiple MyelomaNCT00920556Sirtris, a GSK Company24
已完成
2 期
AST-120 Used to Treat Mild Hepatic EncephalopathyMild Hepatic EncephalopathyNCT00867698Ocera Therapeutics148